Sean Ellis Biography and Net Worth

Director of Entera Bio

Sean Ellis has served as a member of our Board since June 2019. Mr. Ellis brings extensive knowledge of both life sciences and the U.S. financial markets, with a longstanding history in asset management. Mr. Ellis is a fund manager of Centillion Fund, a venture capital fund dedicated to Israeli investments, with a primary focus on investments in the biotech and related healthcare industries. Centillion is one of Entera Bio’s earliest investors and largest shareholders.

He holds a BA from New York University and MBA from Columbia University.

What is Sean Ellis' net worth?: The estimated net worth of Sean Ellis is at least $620.72 thousand as of March 5th, 2026. Ellis owns 188,098 shares of Entera Bio stock worth more than $620,723 as of August 21st. This net worth estimate does not reflect any other investments that Ellis may own. Learn More about Sean Ellis' net worth.
How do I contact Sean Ellis?: The corporate mailing address for Ellis and other Entera Bio executives is FIFTH FLOOR KIRYAT HADASSAH MINRAV BUILDING, JERUSALEM L3, 9112002. Entera Bio can also be reached via phone at (722) 532-7151 and via email at [email protected]. Learn More on Sean Ellis' contact information.
Has Sean Ellis been buying or selling shares of Entera Bio?: Sean Ellis has not been actively trading shares of Entera Bio during the past quarter. Most recently, on Thursday, March 5th, Sean Ellis bought 10,000 shares of Entera Bio stock. The stock was acquired at an average cost of $1.23 per share, with a total value of $12,300.00. Following the completion of the transaction, the director now directly owns 188,098 shares of the company's stock, valued at $231,360.54. Learn More on Sean Ellis' trading history.
Who are Entera Bio's active insiders?: Entera Bio's insider roster includes Sean Ellis (Director), Geno Germano (Director), Yonatan Malca (Director), Ron Mayron (Director), Ramesh Ratan (CFO), and Miranda Toledano (CEO). Learn More on Entera Bio's active insiders.
Are insiders buying or selling shares of Entera Bio?: In the last year, Entera Bio insiders bought shares 5 times. They purchased a total of 69,000 shares worth more than $92,530.00. The most recent insider tranaction occured on March, 9th when Director Geno J Germano bought 20,000 shares worth more than $26,000.00. Insiders at Entera Bio own 10.6% of the company. Learn More about insider trades at Entera Bio.
Information on this page was last updated on 3/9/2026.

Sean Ellis Insider Trading History at Entera Bio

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/5/2026	Buy	10,000	$1.23	$12,300.00	188,098
2/9/2026	Buy	18,000	$1.24	$22,320.00	178,098
8/21/2023	Buy	40,000	$0.60	$24,000.00	102,100
11/11/2022	Buy	30,000	$0.53	$15,900.00	62,100
7/21/2022	Buy	14,900	$1.64	$24,436.00	32,100

Sean Ellis Buying and Selling Activity at Entera Bio

Entera Bio Company Overview

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

Today's Range

Now: $3.28

$3.18

$3.34

50 Day Range

MA: $2.16

$1.18

$3.92

2 Week Range

Now: $3.28

$0.91

$4.20

Volume

150,031 shs

Average Volume

1,127,548 shs

Market Capitalization

$567.91 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.38